Volume 24 - Issue 11 - November 2016
11/21/2016
The FDA recently awarded 21 new clinical trial research grants totaling more than $23 million over the next 4 years to boost the development of products for patients with rare diseases.
The FDA recently awarded 21 new clinical trial research grants totaling more than $23 million over the next 4 years to boost the development of products for patients with rare diseases.
The FDA recently awarded 21 new...
11/21/2016
The Dermatologist
11/21/2016
Topical diacerein 1% met its primary efficacy endpoint in a study of patients with epidermolysis bullosa simplex (EBS), according to final results from a phase 2 study presented at the 25th Annual Congress of the European Academy of...
Topical diacerein 1% met its primary efficacy endpoint in a study of patients with epidermolysis bullosa simplex (EBS), according to final results from a phase 2 study presented at the 25th Annual Congress of the European Academy of...
Topical diacerein 1% met its...
11/21/2016
The Dermatologist
12/19/2016
This article outlines critical areas for consideration when undertaking physician partnerships.
This article outlines critical areas for consideration when undertaking physician partnerships.
This article outlines critical...
12/19/2016
The Dermatologist
Chief Medical Editor Message
11/21/2016
I pity the dermatologist who doesn’t realize how good things are.
I pity the dermatologist who doesn’t realize how good things are.
I pity the dermatologist who...
11/21/2016
The Dermatologist
12/18/2016
These apps visually track acne symptoms, remind patients to use medications, and provide patient education information.
These apps visually track acne symptoms, remind patients to use medications, and provide patient education information.
These apps visually track acne...
12/18/2016
The Dermatologist
12/01/2016
The Janus kinase inhibitor tofacitinib (Xeljanz) shows promise for treating severe alopecia areata and its variants in adults and adolescents, according to two retrospective studies.
The Janus kinase inhibitor tofacitinib (Xeljanz) shows promise for treating severe alopecia areata and its variants in adults and adolescents, according to two retrospective studies.
The Janus kinase inhibitor...
12/01/2016
The Dermatologist
11/29/2016
The 2016 conference buzzed with new research, lively exhibits, and networking professions.
The 2016 conference buzzed with new research, lively exhibits, and networking professions.
The 2016 conference buzzed with...
11/29/2016
The Dermatologist
11/23/2016
The FDA recently issued guidelines detailing the data makers of sunscreen that are sold over the counter, need to produce to prove the ingredients in the products are safe and effective.
The FDA recently issued guidelines detailing the data makers of sunscreen that are sold over the counter, need to produce to prove the ingredients in the products are safe and effective.
The FDA recently issued...
11/23/2016
The Dermatologist
11/21/2016
In this case, a 34-year-old woman presented with mildly pruritic and somewhat painful hands of approximately 6 months’ duration.
In this case, a 34-year-old woman presented with mildly pruritic and somewhat painful hands of approximately 6 months’ duration.
In this case, a 34-year-old...
11/21/2016
The Dermatologist
11/21/2016
Posters presented at The Fall Clinical Dermatology Conference-Las Vegas look at new research on treatment options for psoriasis.
Posters presented at The Fall Clinical Dermatology Conference-Las Vegas look at new research on treatment options for psoriasis.
Posters presented at The Fall...
11/21/2016
The Dermatologist
